[Recent study on pathogenesis of bronchial asthma and the therapeutic strategy].
Fukkuda
Takeshi
T
D000280:Administration, Inhalation; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000420:Albuterol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D001249:Asthma / Q000188:drug therapy* / Q000209:etiology*; D001507:Beclomethasone / Q000008:administration & dosage; D001980:Bronchi / Q000166:cytology / Q000503:physiopathology*; D001982:Bronchial Diseases / Q000150:complications; D016535:Bronchial Hyperreactivity / Q000150:complications; D001991:Bronchitis / Q000150:complications; D003251:Constriction, Pathologic / Q000150:complications; D004359:Drug Therapy, Combination; D004802:Eosinophilia / Q000150:complications; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D000068299:Salmeterol Xinafoate; D013806:Theophylline / Q000627:therapeutic use
D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D000068299:Salmeterol Xinafoate; D013806:Theophylline; D001507:Beclomethasone; D000420:Albuterol